Table 1 Participant characteristics
Characteristic | N = 10831 |
|---|---|
Sex | |
Female | 590 (55%) |
Male | 493 (45%) |
Age (years) | |
18–64 | 988 (91%) |
65+ | 95 (9%) |
Infection/vaccination status at the time of most recent serological test | |
Infected only | 634 (58%) |
Vaccinated only | 98 (9%) |
Infected prior to vaccination | 310 (29%) |
Infected after vaccination | 11 (1%) |
Infected prior to vaccination and re-infected after vaccination | 30 (3%) |
Virological confirmation among participants with a history of infection (N = 985) | |
Virologically confirmed infection (self-reported or from ARGOS registry) | 567 (58%) |
No virological confirmation (anti-N positive serology only) | 418 (42%) |
Vaccine type among vaccinated participants at the time of last serological status (N = 449) | |
mRNA-1273 (Moderna/US NIAID) | 247 (55%) |
mRNA-BNT162b2/Comirnaty (Pfizer/BioNTech) | 202 (45%) |
# Positive Roche-S serological samples per participant within this study | |
2 | 603 (55%) |
3 | 374 (35%) |
4 | 104 (10%) |
5 | 1 (<0.1%) |
1n (%) | |
